Background: IDegLira, a fixed-ratio combination of a basal insulin (BI), insulin degludec, and liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), was approved by the FDA in Q4 2016 for the treatment of type 2 diabetes Mellitus (T2DM). This study describes characteristics of adult patients (pts) who initiated IDegLira in a real-world setting.

Methods: Demographic and clinical data for pts prescribed IDegLira between May and November 2017 were extracted from the Practice Fusion ambulatory care database. Pt characteristics were described for the 6-months prior to initiation. Pts were grouped by most recent antidiabetic therapy regimen in the prior 6-months.

Results: Pts prescribed IDegLira (n=388) received one of five prior therapy regimens: BI as only injectable (BI-INJ, N=88), GLP-1 as only injectable (GLP-INJ, N=47), GLP-1+insulin (GLP-INS, N=65), multiple daily insulin injections (MDI, N=35), and no injectable therapy (N-INJ, N=153). On average, IDegLira pts were 58 years old (SD 11.5); the majority (66%) between 40 and 64 years of age. Pts’ mean BMI was 35 (7.6). Mean A1C was 9.0 (1.82), with 12% below <7%, 19% between 7-7.9%, 25% between 8-8.9%, and 44% >9%. The N-INJ group had the highest mean A1C prior to initiating IDegLira (9.6), BI-INJ and GLP-INJ had intermediate means (both 9.0), and the GLP-INS and MDI groups had the lowest (8.4, 8.3). IDegLira patients previously treated with GLP-INS, MDI, and N-INJ had higher Charlson Comorbidity and Diabetes Complication Severity scores compared to patients previously treated with BI-INJ or GLP-INJ. Most prescriptions were written by PCPs (53%).

Conclusion: This analysis shows that initial use of IDegLira has been across a range of practices and clinical profiles. Most IDegLira prescribing occurred among pts on a previous injectable therapy, with those on single injectable therapy having higher A1Cs than those on multiple injectable therapies. Pts prescribed IDegLira with no injectable therapy in the prior 6 months had the highest A1C values.

Disclosure

M. Mocarski: Employee; Self; Novo Nordisk Inc.. Stock/Shareholder; Self; Novo Nordisk A/S. J. da Rocha Fernandes: Employee; Self; Novo Nordisk A/S, International Diabetes Federation. L. Kallenbach: None. J. Vasey: None. J. Ken: None. A.N. Bogdanov: None. M. Radin: Employee; Self; Novo Nordisk Inc. L.E. Egede: Research Support; Self; National Institute of Diabetes and Digestive and Kidney Diseases. Advisory Panel; Self; Novo Nordisk Inc..

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.